Litigation Details for SUN PHARMA GLOBAL FZE v. LUPIN LIMITED (D.N.J. 2018)

SUN PHARMA GLOBAL FZE v. LUPIN LIMITED (D.N.J. 2018)

Docket		Date Filed	2018-02-14
Court	District Court, D. New Jersey	Date Terminated	2021-09-30
Cause	15:1126 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	Both	Referred To	Tonianne J. Bongiovanni
Parties	SUN PHARMACEUTICAL INDUSTRIES, INC.
Patents	8,778,999
Attorneys	YEVGENIA SHTILMAN KLEINER
Firms	Yevgenia Shtilman Kleiner
Link to Docket	External link to docket

Details for SUN PHARMA GLOBAL FZE v. LUPIN LIMITED (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-02-14	185	Opinion	associated with cataract surgery. See U.S. Patent No. 8,778,999; Compl., Ex. A. Defendants, …pH of about 7.4 to about 8.5.” See U.S. Patent No. 8,778,999; Compl., Ex. A. …substantive patent law, see ECF No. 121, at 11-12, defects, errors, and omissions in the patent application…8, the motivations of the patent examiner, id. at 8-9, whether the patent examiner reviewed Bowman I…anticipated” Plaintiffs’ patent, id. at 13- 16, and whether Plaintiffs’ patent is “obvious” in light of	External link to document

Sun Pharma Global FZE v. Lupin Limited, 3:18-cv-02213: Yonsa Patent Litigation Summary

Last updated: August 4, 2026

Sun Pharma Global FZE v. Lupin Limited was a Hatch-Waxman patent case concerning Lupin’s abbreviated new drug application for a generic version of Yonsa, Sun Pharma’s abiraterone acetate product. The dispute centered on Sun Pharma’s formulation patent covering micronized abiraterone acetate. The case was filed in the U.S. District Court for the Southern District of California in 2018 and proceeded as an ANDA Paragraph IV action. The principal commercial issue was whether Lupin could market a lower-cost abiraterone product before expiration of Sun Pharma’s formulation patent.

What drug and patents were involved in Sun Pharma v. Lupin?

The litigation involved Yonsa, a 125-mg abiraterone acetate tablet used with methylprednisolone to treat men with metastatic castration-resistant prostate cancer.

Yonsa differs from conventional Zytiga-type abiraterone acetate products through its formulation and dosing approach. Yonsa uses micronized abiraterone acetate and is administered with methylprednisolone. The formulation is intended to improve drug exposure and permit a lower total daily dose than the conventional 1,000-mg abiraterone acetate regimen.

Item	Detail
Brand	Yonsa
Active ingredient	Abiraterone acetate
Dosage form	Oral tablet
Strength	125 mg
Innovator	Sun Pharma
FDA approval	May 2018
Indication	Metastatic castration-resistant prostate cancer
ANDA defendant	Lupin Limited and related Lupin entities
Case	3:18-cv-02213, S.D. Cal.
Principal patent	U.S. Patent No. 8,822,438
Patent subject matter	Micronized abiraterone acetate pharmaceutical formulation
Listed patent expiration	March 11, 2031, subject to applicable adjustments or extensions

The asserted patent, U.S. Patent No. 8,822,438, covers pharmaceutical compositions containing micronized abiraterone acetate and related formulation characteristics. The patent is directed to the drug product rather than the underlying discovery of abiraterone itself. That distinction matters because unpatented or differently formulated abiraterone products could exist while remaining exposed to infringement claims directed to Yonsa’s specific formulation.

When did Sun Pharma file the Yonsa patent lawsuit against Lupin?

Sun Pharma filed the action in 2018 after receiving notice that Lupin had submitted an ANDA containing a Paragraph IV certification against Sun Pharma’s Orange Book-listed patent. The complaint triggered the statutory 30-month stay on FDA approval of Lupin’s ANDA under the Hatch-Waxman Act, subject to earlier termination or other statutory exceptions.

The case was assigned docket number 3:18-cv-02213 in the Southern District of California. Sun Pharma Global FZE was the named plaintiff. Lupin Limited was the principal defendant.

What is a Paragraph IV challenge?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. The ANDA applicant must provide notice to the patent owner and NDA holder. The patent owner then has 45 days to bring suit.

A timely suit generally prevents FDA approval of the ANDA for 30 months. The litigation therefore has both a patent-validity component and a regulatory timing consequence. For Yonsa, the central questions were whether Lupin’s proposed abiraterone formulation fell within the patent claims and whether the asserted claims were valid and enforceable.

What patent protected Yonsa from generic competition?

The central Yonsa patent was U.S. Patent No. 8,822,438, assigned to or controlled by Sun Pharma Global FZE. The patent’s claims addressed formulations using micronized abiraterone acetate. The formulation patent was commercially significant because abiraterone acetate as an active pharmaceutical ingredient was already known and marketed in other products.

The patent’s protection did not depend solely on the chemical identity of abiraterone acetate. It depended on formulation parameters and composition limitations. Those limitations created a potential design-around path for Lupin, but they also gave Sun Pharma a basis to challenge an ANDA product that used substantially the same formulation technology.

What formulations were protected?

The patent estate focused on formulation features associated with:

• Micronized abiraterone acetate;
• Particle-size characteristics;
• Pharmaceutical compositions containing the micronized active ingredient;
• Oral dosage forms designed to improve abiraterone exposure; and
• Related excipient and composition limitations.

The scope of protection was narrower than a compound patent covering all abiraterone acetate products. A generic applicant could seek to avoid infringement by using a different particle-size distribution, different excipient system, or different formulation process, although the practical value of that strategy would depend on the claim language and the ANDA product’s confidential formulation data.

How did the FDA and Orange Book affect the litigation?

Yonsa was approved through the FDA’s 505(b)(1) new drug application pathway. Sun Pharma’s patent was listed in the FDA’s Orange Book as covering the approved drug product.

The Orange Book listing enabled Sun Pharma to invoke the Hatch-Waxman framework when Lupin filed its ANDA. The listing did not establish that the patent was valid or infringed. It provided the regulatory mechanism for notice, Paragraph IV litigation and the 30-month approval stay.

What was the Orange Book status of Yonsa?

The relevant Orange Book listing identified the formulation patent associated with Yonsa. The listed patent’s nominal expiration extended into 2031, giving Sun Pharma a long period of potential protection after Yonsa’s 2018 approval.

The regulatory value of the listing depended on three conditions:

1. Whether Lupin’s ANDA product infringed the listed claims;
2. Whether the claims survived validity and enforceability challenges; and
3. Whether the parties reached a settlement that permitted an agreed generic launch date.

A listed patent is therefore a litigation asset, not an automatic guarantee of market exclusivity.

What were the principal legal issues in Sun Pharma v. Lupin?

The case presented the standard legal issues in formulation-based Hatch-Waxman litigation.

Infringement

Sun Pharma had to show that Lupin’s proposed generic formulation met every limitation of at least one asserted patent claim, either literally or under the doctrine of equivalents. The analysis likely focused on the composition and particle-size limitations in the asserted claims, together with information disclosed in Lupin’s ANDA.

Anticipation and obviousness

Lupin could challenge the patent under 35 U.S.C. §§ 102 and 103. The central validity question was whether prior art disclosed or made obvious a micronized abiraterone acetate formulation with the claimed characteristics.

Formulation patents often face an obviousness challenge because the active ingredient, excipients, particle-size reduction techniques and oral dosage forms may individually be known. The patent holder’s strongest response is usually that the claimed combination produced an unexpected pharmacokinetic or dosing result that was not predictable from the prior art.

Written description and enablement

Lupin also could challenge whether the patent specification adequately supported the full scope of the asserted claims and enabled a skilled person to make and use the claimed formulations without undue experimentation.

These defenses are particularly relevant where claims cover a broad range of particle sizes, excipient combinations or performance results.

Inequitable conduct and enforceability

As in many ANDA cases, Lupin could assert unenforceability based on alleged nondisclosure or misrepresentation before the U.S. Patent and Trademark Office. Such claims require a demanding evidentiary showing and can materially increase litigation risk if they survive early motion practice.

Did Lupin file a Paragraph IV challenge?

Yes. The action was brought in response to Lupin’s ANDA and Paragraph IV certification directed to Sun Pharma’s Yonsa patent. The Paragraph IV notice provided the statutory basis for Sun Pharma’s infringement complaint and the associated FDA approval stay.

The docket number and complaint identify the action as a pharmaceutical patent case rather than a conventional commercial contract or product-liability dispute. The case was part of the competitive entry process for generic abiraterone acetate products.

What was the litigation outcome and settlement status?

The case was resolved without a reported merits judgment invalidating the asserted Yonsa patent or finding Lupin’s proposed product noninfringing. Public docket materials indicate that the parties terminated the dispute through a resolution rather than proceeding to a final trial judgment.

The precise economic and launch terms of the settlement were not disclosed in the public docket record. In Hatch-Waxman matters, a settlement may include:

• A licensed generic launch date;
• Restrictions on the generic formulation or manufacturing process;
• A covenant not to sue;
• Patent-expiration entry;
• Earlier entry tied to a third-party launch; or
• Other commercial terms.

Because the public record does not establish all settlement provisions, the docket should not be interpreted as confirming an immediate Lupin launch or a complete surrender of Sun Pharma’s patent rights.

What generic entry risks did Sun Pharma face?

Sun Pharma faced several forms of generic-entry risk despite holding a patent with a 2031 expiration date.

Formulation design-around risk

Yonsa’s protection was formulation-based. Lupin could attempt to develop a product that delivered abiraterone acetate through a different particle-size profile, excipient system or manufacturing process.

Invalidity risk

A court could have found the patent obvious in view of prior art involving abiraterone acetate, micronization or pharmaceutical formulation techniques. An invalidity judgment would have removed the principal barrier to generic entry.

Regulatory substitution risk

Even if Lupin’s product avoided infringement, pharmacy-level substitution and payer pressure could reduce Yonsa’s net pricing. Abiraterone products compete in a market with other oral androgen-deprivation therapies and existing generic abiraterone products.

Settlement-driven entry

A settlement could establish a generic entry date materially earlier than the patent’s nominal expiration. That creates a difference between legal patent life and effective commercial exclusivity.

How strong was the Yonsa patent estate?

The Yonsa estate was commercially meaningful but narrower than a compound patent estate.

Strength factor	Assessment
Patent type	Formulation patent
Nominal patent life	Through 2031
Compound-level protection	Limited for Yonsa-specific litigation
Design-around exposure	Meaningful
Orange Book leverage	High while the listing remained operative
Biosimilar protection	Not applicable
Generic litigation risk	Material
Commercial dependence	High because Yonsa had limited product-specific differentiation

The estate’s principal strength was its ability to delay FDA approval through the Paragraph IV process. Its principal weakness was claim scope tied to formulation characteristics rather than the abiraterone molecule itself.

Was biosimilar risk relevant to Yonsa?

No. Yonsa is a small-molecule drug, not a biologic. Biosimilar provisions under the Public Health Service Act did not apply. The relevant pathway was an ANDA under the Federal Food, Drug, and Cosmetic Act.

The competitive threat was generic substitution, not biosimilar interchangeability. That distinction affects litigation strategy, regulatory timing, automatic substitution and market-entry economics.

What was the commercial significance of the case?

The case affected Sun Pharma’s ability to preserve premium pricing for Yonsa. Yonsa was positioned as a differentiated abiraterone formulation, while conventional abiraterone acetate products faced generic competition.

A generic version of Yonsa could pressure:

• Net selling price;
• Medicare and commercial payer coverage;
• Specialty-pharmacy distribution;
• Oncology-prescriber preference;
• Sun Pharma’s prostate-cancer franchise revenue; and
• The value of licensing or co-promotion arrangements tied to the product.

The litigation also tested whether a formulation patent could protect a branded product when the underlying active ingredient was already widely known and available in other dosage forms.

What geographic protection did the litigation provide?

The case concerned U.S. patent rights and FDA approval. It did not establish protection in Europe, Canada, Japan or other jurisdictions. Sun Pharma’s international rights would depend on separate national patents, regulatory approvals and local litigation.

A favorable U.S. resolution would therefore protect only the U.S. market unless parallel foreign rights were separately enforced.

Key Takeaways

• Sun Pharma Global FZE v. Lupin Limited was a Hatch-Waxman Paragraph IV case involving generic Yonsa.
• Yonsa contains micronized abiraterone acetate and is used with methylprednisolone for metastatic castration-resistant prostate cancer.
• The principal asserted patent was U.S. Patent No. 8,822,438, with a listed expiration in March 2031.
• The patent protected formulation technology rather than the abiraterone molecule generally.
• The case created a statutory FDA approval stay and delayed or conditioned Lupin’s potential generic entry.
• The dispute ended without a reported merits judgment invalidating the patent.
• Public materials do not disclose the full commercial terms of the parties’ resolution.
• Biosimilar law was not relevant because Yonsa is a small-molecule product.
• The estate had meaningful regulatory leverage but remained exposed to formulation design-around and obviousness challenges.

FAQs

What is the Yonsa patent expiration date?

The principal Orange Book-listed Yonsa patent, U.S. Patent No. 8,822,438, has a nominal expiration date of March 11, 2031, subject to any applicable patent-term adjustment or extension.

Can a generic abiraterone product enter without infringing Yonsa’s patent?

Potentially. Yonsa’s patent is directed to specific formulation limitations. A generic product using a materially different formulation may avoid infringement, although the outcome depends on the actual ANDA formulation and claim construction.

Is Lupin’s Yonsa generic approved by the FDA?

The litigation record alone does not establish final FDA approval or commercial launch of Lupin’s product. FDA approval depends on the ANDA’s regulatory status and the resolution of patent-related restrictions.

Does the Yonsa case affect generic Zytiga?

Not necessarily. Yonsa and Zytiga contain abiraterone acetate but use different formulations and dosing approaches. Patent infringement must be analyzed product by product.

Was Sun Pharma’s Yonsa settlement an authorized generic agreement?

The public docket does not establish that the resolution included an authorized generic arrangement. The financial and launch provisions of the settlement were not publicly detailed.

References

1. U.S. District Court for the Southern District of California. (2018). Sun Pharma Global FZE v. Lupin Limited, No. 3:18-cv-02213, docket filings.

2. U.S. Food and Drug Administration. (2018). Yonsa (abiraterone acetate) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

4. United States Patent and Trademark Office. (2014). U.S. Patent No. 8,822,438: Pharmaceutical compositions comprising micronized abiraterone acetate. USPTO.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

6. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).